BVS News and Press, Bioventus Inc. From 05/03/22

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that its subsidiary, Bioventus LLC, has withdrawn its offering of senior notes ...

Beginning July 1, Cigna (NYSE:CI) commercial members will have access to Bioventus' (NASDAQ:BVS) knee arthritis pain treatments Durolane and Gelsyn-3. Both products contain hyaluronic acid. Durolane is a single injection while Gelsyn-3 is three injections. Read why Seeking Alpha contributor T...

DURHAM, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna...

Bioventus (NASDAQ:BVS) has reported Q1 prelim net sales of $116.5M to $118.5M vs. $117.76M consensus. That would indicate a 42% to 45% growth over the prior-year period. Prelim net loss and adj. EBITDA are estimated to be in the range of -$19.4M and -$19M and $6.8M to $7.3M, respectively. The...

DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary financial results for the first quarter ended April 2, 2022. P...

Bioventus (NASDAQ:BVS) is up 3.5% in premarket trading on Tuesday as the company announced its plan of securing $415M in senior notes due 2027. The healthcare supplies company said it intends to use the proceeds to partially fund its CartiHeal's acquisition and to repay a portion of...

DURHAM, N.C., April 26, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that, subject to market conditions, its subsidiary Bioventus LLC (the “Issu...

DURHAM, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2022 be...

Maker of pain treatments and restorative therapies Bioventus (NASDAQ:BVS) announced expanded medical coverage for its TheraSkin product, a cellular and tissue-based treatment indicated for use in applications for the repair of human skin. The company said TheraSkin coverage now includes ...

DURHAM, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that TheraSkin coverage now includes three out of the four largest commercial plan...